Suman Kumar Vodnala

Suman Kumar Vodnala has extensive work experience in the field of immunotherapy and research. Suman Kumar worked as a Senior Director at Lyell Immunopharma starting in November 2019, where they led scientific groups and contributed to the development of cell-based immunotherapies. Suman Kumar'sresponsibilities included strategic leadership, research management, and SWOT analysis.

Before joining Lyell Immunopharma, Suman worked at the National Institutes of Health (NIH) from June 2013 to October 2019 as a Senior Research Scientist. During this time, they focused on understanding immune checkpoints and tumor-specific neo-antigens to enhance T cell immunotherapy. Suman Kumar also conducted research on T cell metabolic fitness in adoptive T cell transfer therapy.

Prior to their role at NIH, Suman worked as a Research Scientist at Karolinska Institutet from June 2007 to May 2013. Suman Kumar'swork involved screening nucleoside analogues against African trypanosomes and other cancer cell lines. Suman Kumar also conducted lead development to inhibit trypanothione reductase.

Suman's career in research began as a Research Assistant at GVK BIO from January 2004 to August 2006, where they focused on the development of inhibitors against cathepsin B using pharmacophore hypothesis.

Suman Kumar Vodnala completed their education in a chronological order. In 2005, they obtained a certification in protein modeling and rational drug designing from Accelrys. From 2006 to 2008, they pursued a Master's degree in Biotechnology at KTH Royal Institute of Technology. Following that, from 2008 to 2013, they attended Karolinska Institutet, where they obtained a Doctor of Philosophy (PhD) degree in Immunology and Drug discovery.